The present invention relates to a novel glycogen dependent hydrodot for oral delivery and sustained release of D- fagomine coupled with D- chiroinositol for treatment and management of diabetes specially diabetes mellitus-2. The hydrogel of glycogen prevents diverse overall activity by specific channelization and prolonging the effect of D- fagomine. When D-chiroinositol is given with Dfagomine, which increases its activity hence less amount of D- fagomine is required for the same activity. This reduces the cost of the treatment as otherwise the drug as a pure compound is of high cost.
